Filing identity and reporting period
Important identity mismatch: The supplied filing is Big Cypress Acquisition Corp.’s Form 10-K, not a filing by SAB Biotherapeutics, Inc. The text does not establish a connection between the two companies. It covers Big Cypress’s inception-to-date period, November 12 through December 31, 2020; the IPO occurred after year-end, on January 14, 2021.
Big Cypress was a blank-check company seeking a business combination, with stated interest in the life sciences industry. At December 31, it had not selected a target or begun substantive discussions with one.
Financial performance and position
| Metric | Reported amount or detail |
|---|---|
| Revenue | None; the company had not commenced operations. |
| Net loss | $8,996 for the inception-to-December 31 period, consisting of formation and operating costs. |
| Cash flow | $10,032 used in operating activities; $94,868 provided by financing activities; ending cash was $84,836. |
| Cash and current assets | Cash of $84,836; total current assets of $87,094. |
| Total assets | $322,205, including $235,111 of deferred offering costs. |
| Liabilities and equity | Current liabilities of $306,201, including a $150,000 related-party promissory note; stockholders’ equity of $16,004. No long-term debt was reported. |
| Working capital | Deficit of $219,107, excluding deferred offering costs. |
| Margins and comparable-period changes | Not meaningful for a pre-operational company. No prior comparable operating period is provided because the company was formed in November 2020. |
The financial statements received an unqualified audit opinion. Management reported effective disclosure controls as of year-end; the filing omits management’s internal-control assessment and auditor attestation under the SEC transition period for newly public companies.
Material subsequent events, outlook, and risks
- IPO and liquidity after year-end: On January 14, 2021, the company sold 11.5 million public units for $115 million and 417,200 private units for $4.172 million. It placed $116.15 million in the trust account and reported approximately $1.2 million outside the trust. IPO transaction costs were $6.038 million, including $4.221 million of deferred underwriting fees payable only if a business combination is completed.
- Business-combination deadline: The company had 15 months from the IPO closing to complete a combination, with a possible extension up to 21 months. If it fails, it must redeem public shares and liquidate, subject to the filing’s terms.
- Funding and contingency risks: Management expected available working capital and borrowing capacity to cover needs through a combination or one year from the filing, but acknowledged that cost overruns or redemption demands could require additional financing. The sponsor’s trust-account indemnity may not be collectible; the company said it had not verified the sponsor’s ability to pay.
- COVID-19: Management said a negative impact on financial position, operations, or the target search was reasonably possible, but not quantifiable; the statements included no adjustments for this uncertainty.
- Conflicts and related parties: The sponsor receives a $10,000 monthly administrative-services fee beginning in January 2021. Potential conflicts include management’s other fiduciary obligations, sponsor-related financing, and possible transaction or post-combination compensation. Certain insider loans of up to $1.5 million may be convertible into private units.
- Other terms: Public warrants generally have an $11.50 exercise price and are subject to specified exercise, redemption, and adjustment provisions. The company reported no legal proceedings or off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the intended issuer: this filing identifies Big Cypress Acquisition Corp., not SAB Biotherapeutics, Inc.
- Review the IPO trust balance, funds available outside the trust, transaction expenses, and the deferred underwriting fee.
- Check the business-combination deadline, any extension, redemption provisions, and consequences if no transaction closes.
- Assess the sponsor’s ability to satisfy its trust indemnity and the terms of any future insider loans or financing.
- Review target-selection progress, conflicts of interest, related-party payments, and any proposed transaction’s dilution and warrant terms.